San Antonio's CTRC launches new clinical trial for brain cancer treatment

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor — thanks in part to new technology developed at the Cancer Therapy &Research Center at The University of Texas Health Science Center at San Antonio. The concept was developed by nuclear medicine physician William Phillips, biochemist Beth A. Goins and Ande Bao, a medical physicist and pharmaceutical chemist. All of the work took place in the School of Medicine at the Health…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

AbstractCraniotomy surgical site infections are an inherent risk and dreaded complication for the elective brain tumor patient. Sequelae can include delays in resumption in adjuvant treatments for multiple surgeries if staged cranioplasty is pursued. Here, the authors review their experience in operative debridement of surgical site infections with single-stage reimplantation of the salvaged craniotomy bone flap. A prospectively maintained database of a single surgeon ’s neuro-oncology patients from 2009 to 2017 (JRF) was queried to identify 11 patients with surgical site infection after craniotomy for tumor resectio...
Source: Neurosurgical Review - Category: Neurosurgery Source Type: research
A major limitation of targeted cancer therapy is the rapid emergence of drug resistance, which often arises through mutations at or downstream of the drug target or through intrinsic resistance of subpopulations of tumor cells. Medulloblastoma (MB), the most common pediatric brain tumor, is no exception, and MBs that are driven by sonic hedgehog (SHH) signaling are particularly aggressive and drug-resistant. To find new drug targets and therapeutics for MB that may be less susceptible to common resistance mechanisms, we used a developmental phosphoproteomics approach in murine granule neuron precursors (GNPs), the developm...
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Research Articles Source Type: news
MT, Elias JE, Scott MP Abstract A major limitation of targeted cancer therapy is the rapid emergence of drug resistance, which often arises through mutations at or downstream of the drug target or through intrinsic resistance of subpopulations of tumor cells. Medulloblastoma (MB), the most common pediatric brain tumor, is no exception, and MBs that are driven by sonic hedgehog (SHH) signaling are particularly aggressive and drug-resistant. To find new drug targets and therapeutics for MB that may be less susceptible to common resistance mechanisms, we used a developmental phosphoproteomics approach in murine granu...
Source: Science Signaling - Category: Biomedical Science Authors: Tags: Sci Signal Source Type: research
Abstract Sorcin (Soluble resistance related calcium binding protein) is a small soluble penta EF family (PEF) of calcium (Ca2+) binding protein (22,000 Da). It has been reported to play crucial roles in the regulation of calcium homeostasis, apoptosis, vesicle trafficking, cancer development, and multidrug resistance (MDR). Overexpression of sorcin has been reported to be associated with different cancers such as breast cancer, colorectal cancer, gastric cancer, leukemia, lung cancer, nasopharyngeal cancer, ovarian cancer, etc. Essentially, expression of sorcin has been found to be elevated in cancer cells as comp...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Researchers at Washington University in St. Louis have developed a new method to bypass the blood-brain barrier and deliver drugs to the brain, which could be particularly useful in difficult-to-treat brain tumors. The technique involves adminis...
Source: Medgadget - Category: Medical Devices Authors: Tags: ENT Neurology Neurosurgery Oncology Source Type: blogs
Conclusion: These results open a new window for establishment promising approaches with the concept of anti-cancer therapy by nisin in the future. PMID: 30139228 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Credit: Christine Daniloff/MIT A team of researchers from Brigham &Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to check for a mutation linked to glioma and implanted microparticles that slowly elute drug over the course of several days or even weeks to treat the brain cancer. Get the full story at our sister site, D...
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Brigham & Women's Hospital Massachusetts General Hospital Massachusetts Institute of Technology Source Type: news
PET scans with the radiotracer F-18 fluorothymidine (FLT) can help determine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET, MRI may predict pediatric brain tumor outcomes FDG-PET/CT beats FLT-PET/CT for differentiated thyroid cancer FLT-PET could help predict outcome in head and neck cancer JNM: FLT-PET aids prognosis of glioma patients FLT-PET helps predicts cancer therapy results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Abstract In recent years, we have witnessed a significant increase in the amount of studies using Mesenchymal Stem Cells (MSCs) for cancer therapy, mostly as vectors for drug or gene delivery strategies. This is because of their intrinsic capacity of homing into tumor niches. However, the interactions between MSCs themselves and tumor cells is not fully understood, with contradictory results frequently being observed regarding their effects on cancer cell invasion and proliferation. This poses an important question of safety in respect to the application of these cells. The source of the MSC population used, as we...
Source: Biochimie - Category: Biochemistry Authors: Tags: Biochimie Source Type: research
Authors: Sun S, Du G, Xue J, Ma J, Ge M, Wang H, Tian J Abstract Indoleamine 2,3-dioxygenase (IDO), which is highly expressed in human glioblastoma and involved in tumor immune escape and resistance to chemotherapy, is clinically correlated with tumor progression and poor clinical outcomes, and is a promising therapeutic target for glioblastoma. IDO inhibitors are marginally efficacious as single-agents; therefore, combination with other therapies holds promise for cancer therapy. The aim of this study was to investigate the anti-tumor effects and mechanisms of the IDO inhibitor PCC0208009 in combination with temoz...
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Tags: Int J Immunopathol Pharmacol Source Type: research
More News: Biochemistry | Biotechnology | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Clinical Trials | Health | Health Management | Neurology | Nuclear Medicine | Physics | Science | Texas University